|
COPD Tops Asthma as the Focus Indication for Next Generation Respiratory …
MarketWatch (press release) COPD has superseded asthma as the lead indication in the market race, most likely due to the FDA's new safety controls pertaining to limited use of all LABA-containing drugs in asthma as well as the unmet need for improved therapies for COPD," states … |
View full post on asthma – Google News